ABSTRACT A physiologically based pharmacokinetic model was used to amalgamate information obtained in rats and man by various routes of exposure to trichloroethylene (TRI) and tetrachloroethylene (TETRA). Since there have been no pharmacokinetic data on drinking water exposure, drinking water exposure to TRI was conducted in rats using '4C-TRI. Several partition coefficients ofTRI and TETRA were also determined in the present study. Simulations ofthe kinetics of TRI and TETRA were made with the unified physiologically based pharmacokinetic model to determine whether reported pharmacokinetic data from different routes of exposure to TRI and TETRA (inhalation, intravenous, drinking water in rats, and inhalation in man) could be simulated. The results indicated that the unified model used in this study successfully simulates the pharmacokinetics of TRI and TETRA irrespective of the routes and exposure intensities. Subsequently, sensitivity analyses were performed. Since both TRI and TETRA require bioactivation to produce their toxicity, the amounts metabolised in the body were used as indicators oftoxicity. Vmax (maximum velocity ofmetabolism in the liver), alveolar ventilation, and the blood/air partition coefficient had a more profound effect than other factors on the amounts of these chemicals metabolised when parameter values were altered. The model was applied to simulate the biologically permissible values of exhaled air concentration and blood concentration of these compounds for monitoring exposure intensities in occupational settings. The simulated maximum permissible values showed good agreement with those obtained by field studies. Finally, the model was applied to the risk assessment of drinking water exposures to TRI and TETRA, assuming that a man weighing 70 kg drinks 2 1 of the most contaminated drinking water ever reported in the US; 32 ppb for TRI and 5 ppb for TETRA. The simulated metabolised amounts of TRI and TETRA under steady state condition in man were a fifth of an order of magnitude lower than non-cancer causing metabolised amounts of TRI and TETRA in rats through inhalation.
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One of the tasks of toxicology is to provide information on the risk to man from exposure to environmental contaminants. Toxicological data are mostly limited to animals except in cases where human data are incidentally collected after accidental exposures. Therefore, in most cases dose response relations established in animals have been used to assess the human risk. The basis of this approach resides in the concept that animals may be sensitive substitutes for the prediction of human toxicity. This assumption is hypothetical yet widely accepted and has been treated as the axiom for rationalising animal experimentation.
Accepted 21 March 1988 In addition to this assumption, there remains another gap between animal experiments and real conditions ofhuman exposure; the exposure routes in man are not necessarily the same as those in the animal experiments. In animal experiments the dose may imply either the amount of chemicals injected or the concentration of chemicals in feed, or the exposure concentration in the inspired air. Thus the constants derived from these results are usually expressed as constants in a route dependent manner such as LC50, LD50, and LT50. From the viewpoint of human risk assessment, however, doses expressed by the route dependent manner have limited applications.
The core assumption ofthe dose response analysis is 239 240 that there exists a direct correspondence between the dose or inspired air concentration and the "effective concentration x time" in the body. Therefore, if the internally achieved concentration x time products in the body are estimated from the external doses, a uniform dose response relation may be established in a route independent manner.'
The physiologically based pharmacokinetic model (PPM) appears to be a promising tool for obtaining dose response relations on the basis of inner doses,' and thus enables the calculation of the internally achieved concentration x time products in man by scaling up from animals.2 By contrast, interspecies extrapolation is impossible by conventional compartment pharmacokinetic modelling because parameters in the compartment model do not have a sound physiological basis.2 A drawback of PPM, however, is that it requires more information than compartment models including metabolic constants, tissue/blood partition coefficients, and cardiac output. Vmax (maximum velocity of metabolism) and km (Michaelis constant) in animals/man and the partition coefficients in human tissues are especially difficult to obtain from reports and even when found, may vary by an order of magnitude. Therefore, unavoidable errors in parameter values may result in cumulative errors which may affect the simulated results. PPM can be described with a set of non-linear differential equations and, theoretically, the sensitivity ofthe simulated results to changes in the parameters should differ; small changes in some parameters may have profound influences on simulation results whereas changes in other parameters do not. Owing to non-linearity of the equations, the sensitivity is also a function of the dose: some parameters may have a more predominant influence at unsaturated levels, whereas the reverse may be the case for other parameters. Thus a logical question is, to what degree do perturbations of the individual parameters affect the final simulation results at a given dose?
The present study was conducted with the hope of establishing algorithms in applying a physiologically based pharmacokinetic model in animals to human toxicology. Firstly, the applicability of the five tissue compartment model to a pair of prototype chemicals, a highly metabolised compound, and a poorly metabolised compound was examined. Trichloroethyelene (TRI) and tetrachloroethylene (TETRA) were selected as examples of the former and latter compounds, respectively.3 In this process the model was applied to exposure monitoring in occupational settings. Secondly, sensitivity analyses by changing parameter values was carried out to find more determinative parameters. Finally, this model was applied to the human risk assessment of TRI and TETRA via drinking water ingestion.
Koizumi Materials and methods

DRINKING WATER EXPOSURE
The drinking water exposure experiment was conducted using rats. Radioactive trichloroethylene (14C-TRI; uniformly labelled) of specific activity IIa3 mCi/ mmol was obtained from New England Nuclear. The radiochemical purity after purification was found to be more than 98%. For administration to Flow to the tissue groups-Flow to the individual tissue groups was obtained from the product of the relative percentage of flow to each tissue and appropriate cardiac output. It was assumed that the same percentage of cardiac output would perfuse the tissue groups in rat and man and the percentages were taken from the paper of Davis and Mapleson.5 PARTITION 
COEFFICIENTS
Tissue/air partition coefficients were determined for human blood and rat blood, liver, fat, and muscle using the vial equilibrium technique of Sato and Nakajima.6 On the sampling date, blood and tissues were collected from three male rats. Blood and tissues were then pooled. Liver and muscle were homogenised with isotonic saline solution (25%w/w). When liver or muscle/air partition coefficient was calculated, the dilution of the homogenates with saline was compensated by a method described by Sato and Nakajima.6
Fat tissues were pulverised at the temperature ofliquid nitrogen and then pooled. Human blood samples were collected from three male volunteers on the day of the determination and measured individually. Tissue or blood air partition coefficients were determined by a gas chromatographic method, using a Perkin-Elmermodel F-45 head space analyser equipped with a flame ionisation detector and a Hewlett Packard model 3388 A integrator. Tissue/blood partition coefficients for rat fat, muscle, and liver were calculated by the ratio of the measured tissue/air partition coefficient by the blood/air coefficient for rat blood. Tissue/blood coefficients for man were estimated by dividing the measured tissue/air coefficient for corresponding rat tissue by the blood/air coefficient for man.
MAXIMUM METABOLIC VELOCITY (VMAX) AND MICHAELIS CONSTANT (KM)
The Vmax and km in the model were estimated in the stepwise manner. When the exposure intensity is substantially less than metabolic saturation, the nonlinear term in the Michaelis-Menten equations may be approximated as:
where Vmax, km, C,, and P, are constants used in the model (table 1) and K is equal to Vmax/km. Thus the equation may be treated as a first order kinetic. The value K was obtained by optimisation and once obtained, the equation may be written using Vmax and k:
Km + (C1/P1) Vmax/K + (Cj/P1) Hence Vmax will be optimised using the known K, based on data after the exposure to doses that saturate the metabolism. Koizumi In the present study the approximate values ofK for TRI and TETRA were estimated from the data on amounts metabolised after inhalation exposure at 10 ppm for six hours generated by Stott et al ' 
SIMULATION OF PHARMACOKINETICS OF TRI AFTER VARIOUS ROUTES OF EXPOSURE IN RATS AND MAN
The physiological model, which uses the parameters in tables 2 and 3, was applied to the fates of TRI after several routes of exposure in rats and man. The various sources of data used are cited in table 4. Estimation of Vmax and Kn-Vmax and Km for TRI were estimated from metabolised amounts reported by Stott et al ' after exposure to 10 ppm and 600 ppm for six hours. At the latter exposure intensity, the metabolism ofTRI was saturated. The obtained Vmax and Km (standardised to 1 kg body weight) was 10 mg/h and 2 5 mg/l, respectively. The body burdens (mg eq ofTRI/kg) for these exposures simulated using the Vmax and Km are 5 56 at 10 ppm and 240 at 600 ppm whereas the observed body burdens corresponding to these exposure intensities were 4-7 and 141, respectively (table 5) . Finally, the simulated proportions of the total body burden uptake of TRI exhaled showed a good agreement with those observed (simulated %/observed %) 31 8%/211% at 600 ppm and 2-6%/2-1% at 10 ppm.
Drinking water exposure in rats-In the simulations it was assumed that TRI ingested with water directly enters the liver as expressed in zero order kinetics (fig  1; K0) . It was also assumed that rats drank water authors clearly show that the metabolism of TETRA was heavily saturated at 600 ppm exposure with 68% being exhaled as a parent compound at 10 ppm, and 88% at 600 ppm. The obtained Vmax and Km (standardised to 1 kg body weight) were 0 5278 mg/h and 1 0 mg/l respectively). Table 7 shows the reported and simulated body burdens. The rates of exhalation of TETRA after inhalations at 600 ppm and 10 ppm were simulated from the end ofthe exposure up to 60 h (fig 4) . Blood concentrations were also simulated (fig 4) .
Drinking water exposure in rats-Frantz and Watanabe have generated pharmacokinetic data on TETRA via drinking water ingestion.4 They reported that the percentage exhaled as a parent compound was 87-9% whereas simulation gives 70-6%.
Human inhalation-Monster et al investigated the pharmacokinetics of TETRA in human volunteers who were exposed for four hours to 72 or 144 ppm.'2 In that study body burdens were estimated in the same way as in the present study-the product of the difference between exhaled and inhaled concentrations of TETRA and minute volumes. As alveolar ventilation (61/h) was calculated by Monster et a'2 this number was used instead of the scaled up value (4-7 I/h). The body burdens estimated by them after the exposure to 72 ppm or 144 ppm was 455 and 945 mg eq of TETRA, whereas the corresponding estimated values are 432 mg eq ofTETRA at 72 ppm and 863 mg eq of TETRA at 144 ppm ( (1) Determination of blood/air partition coefficients for rats and man, and tissues/air partition coefficients for rats using head space analyses.
(2) Calculation of flows and Vmax was based on the 0-7 power of weight.
(3) Optimisation of Vmax and Km using animal data on the amounts metabolised after non-saturable were high (600 ppm) but at low exposures (10 Non-cancert inducing dose 500 ppm x 6 h/day, 5 days/week 74-6* 600 ppm x 6 h/day, 5 days/week 11 Vmax-in mice appeared to be far greater than in rats.'2325 The larger metabolic capacities for TRI and TETRA in mice than in rats are correlated with the higher incidences of hepatocellular carcinomas in this species than in rats.722-26 In the present study a PPM using the Vmax obtained from rat data was proved to be applicable to fates of these chemicals in man, suggesting that standardised metabolic capacities in rats and man are similar to each other. Thus I believe the use of chronic bioassay data on TRI and TETRA in rats is justifiable to formulate the risks in man, at least on the basis of rule of thumb, posed by these compounds. As shown in table 9, we could compare the risk posed by daily intake of drinking water with the risk posed by inhalation on the basis of internal doses. Using simulation, I could show that the relative risk posed by consuming the drinking water in man was about fifth in order of magnitude less than the non-cancer causing doses for TRI and TETRA in rats (table 9) . If the sensitivity of man to tumours is assumed to be similar or at least close to that of rats, then the maximised human risk posed by the drinking water consumption is conceivably estimated as fifth in order of magnitude less than non-tumour causing doses in rats. The differences of fifth in order of magnitude is too large to be perturbed significantly by small changes of parameters as shown by sensitivity analysis. Thus it may be reasonably speculated that carcinogenic effects due to ingesting TRI and TETRA in drinking water may be negligible, if any. Obviously, however, it is needless to say that for those chemicals to which the sensitivity of man is quite different, or of which target organs or metabolic pathway or mechanism is entirely different, PPM has only limited applicability in risk assessment to amalgamate chronic animal bioassay data.
Another example of application of PPM is to find out maximally permissible values under various conditions. As shown in In conclusion, the use of physiologically based pharmacokinetic model with unified algorithm of parameter estimation seems promising in various fields. This approach will enable us to assess the toxicity ofchemicals in man by compiling diverse dose response relations in animals. 
Appendix
The physiologically based pharmacokinetic model ( fig  1) is described mathematically by a set ofsimultaneous differential equations. The model is composed of five tissues: lung, fat, rapidly perfused tissue, slowly perfused tissues, and liver. The mathematical equations described by Ramsey and Andersen' [Qt + Qalv/N] (Al) (2) (A3)
On cessation of inhalation exposure (or when other routes of administration are used), the vapour concentration in inhaled air is zero. By assuming that alveolar respiration accounts for 70% of total respiration, the vapour concentration in exhaled air is given by C,.h= 0-7 Cw,1 + 0°3 Ci.h (A4) 
